On­coRe­sponse wraps Se­ries A with $22.5M; Plot­ting IPO, BerGen­Bio part­ners with Mer­ck on can­cer com­bos

→ The im­muno-on­col­o­gy an­ti­body dis­cov­ery com­pa­ny On­coRe­sponse, cre­at­ed by MD An­der­son and Ther­a­clone Sci­ences, just com­plet­ed a long-run­ning Se­ries A with $22.5 mil­lion. The biotech has been piec­ing this to­geth­er for awhile now. Most re­cent­ly in­sid­ers and HT Fam­i­ly Of­fice con­tributed to the round, fol­low­ing Bax­al­ta (now Shire), Great­Point Ven­tures, the Helsinn In­vest­ment Fund, Arch Ven­ture Part­ners, Canaan Part­ners, and MD An­der­son, with William Marsh Rice Uni­ver­si­ty and Alexan­dria Re­al Es­tate Eq­ui­ties al­so par­tic­i­pat­ing. “With the fi­nal clos­ing of our Se­ries A, we look ahead to the con­tin­ued de­vel­op­ment of our re­search pro­grams that aim to ex­pand the promise of im­muno-on­col­o­gy by iden­ti­fy­ing ther­a­peu­ti­cal­ly rel­e­vant an­ti­bod­ies from pa­tients with elite re­sponse to can­cer im­munother­a­py in a num­ber of on­col­o­gy in­di­ca­tions,” said CEO Clif­ford Stocks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER